Determinants of adherence to evidence-based therapy after acute myocardial infarction

European Journal of Preventive Cardiology

Volumn 23, Issue 9, 2016, Pages 975-985

  Hamood, Hatem ^a,b   Hamood, Rola ^c   Green, Manfred S ^c   Almog, Ronit ^c  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b Leumit Health Care Services   (Israel)

^c UNIVERSITY OF HAIFA   (Israel)

Author keywords

Acute myocardial infarction; adherence; evidence based medicine; secondary prevention

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; AGED; ARTICLE; CLINICAL FEATURE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONSULTATION; DEMOGRAPHY; DOSE RESPONSE; EVIDENCE BASED PRACTICE; FEMALE; FOLLOW UP; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; ISCHEMIC HEART DISEASE; ISRAEL; JEW; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; PROPORTION OF DAYS COVERED; RETROSPECTIVE STUDY; RISK FACTOR; SECONDARY PREVENTION; SURVIVOR; AGE; AMBULATORY CARE; ATTITUDE TO HEALTH; CHI SQUARE DISTRIBUTION; EVIDENCE BASED MEDICINE; HEART INFARCTION; MIDDLE AGED; ODDS RATIO; PROCEDURES; PSYCHOLOGY; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; AGED; AMBULATORY CARE; CARDIOVASCULAR AGENTS; CHI-SQUARE DISTRIBUTION; COMORBIDITY; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; ISRAEL; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; ODDS RATIO; RETROSPECTIVE STUDIES; RISK FACTORS; SECONDARY PREVENTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 84966938219     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/2047487315597209     Document Type: Article

References (38)

1. Van de Werf F, Bax J, Betriu A, et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: The Task Force on the Management of ST-Segment Elevation Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909-2945.
2. Kjekshus J, Pedersen TR,. Reducing the risk of coronary events: Evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1995; 76: 64C-68C.
3. Mukherjee D, Fang J, Kline-Rogers E, et al. Impact of combination evidence based medical treatment in patients with acute coronary syndromes in various TIMI risk groups. Heart 2005; 91: 381-382.
4. Wei L, Wang J, Thompson P, et al. Adherence to statin treatment and readmission of patients after myocardial infarction: A six year follow up study. Heart 2002; 88: 229-233.
5. Akincigil A, Bowblis JR, Levin C, et al. Long-term adherence to evidence based secondary prevention therapies after acute myocardial infarction. J Gen Intern Med 2008; 23: 115-121.
6. Kulkarni SP, Alexander KP, Lytle B, et al. Long-term adherence with cardiovascular drug regimens. Am Heart J 2006; 151: 185-191.
7. Burkhart PV, Sabate E,. Adherence to long-term therapies: Evidence for action. J Nurs Scholarsh 2003; 35: 207-207.
8. Osterberg L, Blaschke T,. Adherence to medication. N Engl J Med 2005; 353: 487-497.
9. Hamood R. Adherence to evidence-based therapy after acute myocardial infarction and its impact on all-cause mortality. Master's thesis, University of Haifa, Israel, 2013.
10. Rasmussen JN, Chong A, Alter DA,. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007; 297: 177-186.
11. Chodick G, Shalev V, Gerber Y, et al. Long-term persistence with statin treatment in a not-for-profit health maintenance organization: A population-based retrospective cohort study in Israel. Clin Ther 2008; 30: 2167-2179.
12. Shalev V, Chodick G, Silber H, et al. Continuation of statin treatment and all-cause mortality: A population-based cohort study. Arch Intern Med 2009; 169: 260-268.
13. Lai EJ, Grubisic M, Palepu A, et al. Cardiac medication prescribing and adherence after acute myocardial infarction in Chinese and South Asian Canadian patients. BMC Cardiovasc Disord 2011; 11: 56-63.
14. Kramer JM, Hammill B, Anstrom KJ, et al. National evaluation of adherence to beta-blocker therapy for 1 year after acute myocardial infarction in patients with commercial health insurance. Am Heart J 2006; 152: 454.e1-454.e8.
15. Schneeweiss S, Patrick AR, Maclure M, et al. Adherence to statin therapy under drug cost sharing in patients with and without acute myocardial infarction: A population-based natural experiment. Circulation 2007; 115: 2128-2135.
16. Wei L, Fahey T, MacDonald TM,. Adherence to statin or aspirin or both in patients with established cardiovascular disease: Exploring healthy behaviour vs. drug effects and 10-year follow-up of outcome. Br J Clin Pharmacol 2008; 66: 110-116.
17. Choudhry N, Glynn R, Avorn J, et al. Untangling the relationship between medication adherence and post-myocardial infarction outcomes: Medication adherence and clinical outcomes. Am Heart J 2014; 167: 51-58.
18. Butler J, Arbogast PG, BeLue R, et al. Outpatient adherence to beta-blocker therapy after acute myocardial infarction. J Am Coll Cardiol 2002; 40: 1589-1595.
19. Figueiras A, Domenech-Massons JM, Cadarso C,. Regression models: Calculating the confidence interval of effects in the presence of interactions. Stat Med 1998; 17: 2099-2105.
20. Anfanger S, Grotto I, Reuveni H, et al. Adherence to secondary prevention guidelines after myocardial infarction is still poor. In: ACSIS conference, 31 December 2010, Tel-Aviv, Israel, The Israel Heart Society.
21. Ho PM, Spertus JA, Masoudi FA, et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006; 166: 1842-1847.
22. Brown MT, Bussell JK,. Medication adherence: WHO cares? Mayo Clin Proc 2011; 86: 304-314.
23. ACSIS. Survey findings and temporal trends 2000-2010. In: ACSIS conference, 31 December 31 2010, Tel-Aviv, Israel, The Israel Heart Society.
24. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Long-term compliance with beta-blockers, angiotensin-converting enzyme inhibitors, and statins after acute myocardial infarction. Eur Heart J 2006; 27: 1153-1158.
25. Ellis JJ, Erickson SR, Stevenson JG, et al. Suboptimal statin adherence and discontinuation in primary and secondary prevention populations. J Gen Intern Med 2004; 19: 638-645.
26. Ho PM, Bryson CL, Rumsfeld JS,. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009; 119: 3028-3035.
27. Crowley MJ, Zullig LL, Shah BR, et al. Medication non-adherence after myocardial infarction: an exploration of modifying factors. J Gen Intern Med 2015; 30: 83-90.
28. Nelson K, Norris K, Mangione CM,. Disparities in the diagnosis and pharmacologic treatment of high serum cholesterol by race and ethnicity: data from the Third National Health and Nutrition Examination Survey. Arch Intern Med 2002; 162: 929-935.
29. Thakkar JB, Chow CK,. Adherence to secondary prevention therapies in acute coronary syndrome. Med J Aust 2014; 201: S106-S109.
30. Lauffenburger JC, Robinson JG, Oramasionwu C, et al. Racial/ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly medicare part d beneficiaries after acute myocardial infarction. Circulation 2014; 129: 754-763.
31. Baron-Epel O, Garty N, Green MS,. Inequalities in use of health services among Jews and Arabs in Israel. Health Serv Res 2007; 42: 1008-1019.
32. Kumbhani DJ, Fonarow GC, Cannon CP, et al. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med 2013; 126: 74.e1-74.e9.
33. Maio V, Marino M, Robeson M, et al. Beta-blocker initiation and adherence after hospitalization for acute myocardial infarction. Eur J Cardiovasc Prev Rehabil 2011; 18: 438-445.
34. Jackevicius CA, Li P, Tu JV,. Prevalence, predictors, and outcomes of primary nonadherence after acute myocardial infarction. Circulation 2008; 117: 1028-1036.
35. Eagle KA, Kline-Rogers E, Goodman SG, et al. Adherence to evidence-based therapies after discharge for acute coronary syndromes: an ongoing prospective, observational study. Am J Med 2004; 117: 73-81.
36. Gislason GH, Rasmussen JN, Abildstrom SZ, et al. Persistent use of evidence-based pharmacotherapy in heart failure is associated with improved outcomes. Circulation 2007; 116: 737-744.
37. Reuter H, Markhof A, Scholz S, et al. Long-term medication adherence in patients with ST-elevation myocardial infarction and primary percutaneous coronary intervention. Eur J Prev Cardiol. Epub ahead of print 12 June 2014. DOI: 10.1177/2047487314540385.
38. Grymonpre R, Cheang M, Fraser M, et al. Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 2006; 44: 471-477.